The Australian Type 1 Diabetes Clinical Research Network has partnered with the Immune Tolerance Network to launch a new Australian clinical trial to slow the development of newly diagnosed type 1 diabetes in children.
The EXTEND-P trial is expected to begin recruitment in March 2016 to test the ability of an existing drug called tocilizumab to preserve beta cell function. Tocilizumab, sold under the brand name Actemra, is currently approved for use in children with juvenile arthritis. Read More
People with type 1 diabetes (T1D) may be able to preserve their remaining beta cells with alefacept, a drug normally used for psoriasis.
A recent clinical trial has shown that alefacept was able to slow or halt the progression of beta cell destruction in people newly diagnosed with T1D, even two years after completing treatment. Read More
A study at the Women’s and Children’s Hospital in Adelaide has shown that adolescents with type 1 diabetes have a faster than normal gastric (stomach) emptying time. This rapid digestion of carbohydrate-containing meals can lead to higher blood glucose levels after eating, impacting long-term blood glucose control.
The study compared the gastric emptying time of 30 adolescents with T1D with age- and sex-matched controls following a standardised meal. The median time taken for half of the meal to be emptied from the stomach was 78 minutes in adolescents with T1D, compared with 109 minutes in controls. Faster gastric emptying resulted in higher blood glucose levels after the meal. Read More